Stop STALLING Act

S 148, the Stop STALLING Act, targets pharmaceutical companies that file sham petitions to delay generic drug approvals. It authorizes the Federal Trade Commission (FTC) to penalize companies submitting objectively baseless petitions under FDA drug approval processes, which are deemed to interfere with competitors' business. Penalties include up to $50,000 per day a sham petition was under review or revenue from drug sales during the delay. The bill directly affects brand-name drug manufacturers (who may file such petitions) and generic drug developers (who face delays), with enforcement triggered by the Secretary of Health and Human Services' determination of delay intent. It applies to petitions filed after enactment and does not alter existing antitrust laws.